Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

被引：11
|
作者：
Jain, Nitin [1 ]
Thompson, Philip A. [1 ]
Burger, Jan A. [1 ]
Ferrajoli, Alessandra [1 ]
Borthakur, Gautam [2 ]
Bose, Prithviraj [1 ]
Estrov, Zeev E. [1 ]
Kadia, Tapan M. [1 ]
Takahashi, Koichi [1 ]
Garg, Naveen [3 ]
Wang, Xuemei [4 ]
Kanagal-Shamanna, Rashmi [5 ]
Patel, Keyur [5 ]
Lopez, Wanda [1 ]
Ayala, Ana [1 ]
Plunkett, William [6 ]
Gandhi, Varsha [6 ]
Kantarjian, Hagop M. [1 ]
O'Brien, Susan M. [7 ]
Keating, Michael J. [1 ]
Wierda, William G. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[7] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-185
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
695
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
    Allan, John N.
    Shanafelt, Tait
    Wiestner, Adrian
    Moreno, Carol
    O'Brien, Susan M.
    Li, Jianling
    Krigsfeld, Gabriel
    Dean, James P.
    Ahn, Inhye E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) : 947 - 953
  • [42] Epidemiological Characterization and Determination of TP53 and IGHV Mutational Status of a Large Series of Previously-Untreated Chronic Lymphocytic Leukemia (CLL) Patients in Spain: The Epicll Study
    Terol, Maria Jose
    Serrano, Alicia
    Lores, Blanca Ferrer
    Bosch, Francesc
    Diaz, Marcos Gonzalez
    Crespo, Marta
    Alcoceba, Miguel
    Fuentes, Azahara
    Chaves, Javier F.
    Esteve, Lucia
    Loriente, Cristina
    Villanueva, Miguel
    BLOOD, 2021, 138
  • [43] Copy Number Aberrations are Significantly Increased in High-Risk, Untreated CLL Patients with Chromosome 17p Deletion and TP53 Mutation
    Stone, A.
    Carter, W.
    Frederick, L.
    Zent, C. S.
    Viswanatha, D. S.
    Schichman, S. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 870 - 870
  • [44] ONE OUT OF FOUR TREATMENT-NAIVE CLL PATIENTS IN TAIWAN CARRY TP53 MUTATIONS: CLINICAL AND PATHOGENETIC IMPLICATIONS
    Wu, S. J.
    Lin, C. T.
    Agathangelidis, A.
    Lin, L. I.
    Ghia, P.
    Tien, H. F.
    HAEMATOLOGICA, 2015, 100 : 424 - 424
  • [45] Genetic aberrations of TP53 predicts response to fludarabine as first line therapy in patients with chronic lymphocytic leukemia on advanced stage Rai III/IV.
    Dero, MD
    Valganon, M
    Agirre, X
    Roman, JP
    Lahortiga, I
    Rubio-Martinez, A
    Rubio-Felix, D
    Novo, FJ
    Giraido, P
    Calasanz, MJ
    BLOOD, 2003, 102 (11) : 668A - 668A
  • [46] The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study
    Yang, Ping
    Liu, Shuozi
    Zhang, Weilong
    Wang, Jing
    Chen, Yingtong
    Jing, Hongmei
    BLOOD, 2023, 142
  • [47] Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
    B Smith-Sørensen
    J Kaern
    R Holm
    A Dørum
    C Tropé
    AL Børresen-Dale
    British Journal of Cancer, 1998, 78 : 375 - 381
  • [48] Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
    Smith-Sorensen, B
    Kærn, J
    Holm, R
    Dorum, A
    Tropé, C
    Borresen-Dale, AL
    BRITISH JOURNAL OF CANCER, 1998, 78 (03) : 375 - 381
  • [49] Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact
    Malcikova, Jitka
    Pavlova, Sarka
    Vonkova, Barbara
    Kotaskova, Jana
    Radova, Lenka
    Plevova, Karla
    Zenatova, Marcela
    Hynst, Jakub
    Dvorackova, Barbara
    Panovska, Anna
    Brychtova, Yvona
    Tichy, Boris
    Navrkalova, Veronika
    Pal, Karol
    Mayer, Jiri
    Doubek, Michael
    Pospisilova, Sarka
    LEUKEMIA & LYMPHOMA, 2020, 61 : 222 - 224
  • [50] IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide
    Karim Maloum
    Catherine Settegrana
    Elise Chapiro
    Bruno Cazin
    Stéphane Leprêtre
    Alain Delmer
    Michel Leporrier
    Brigitte Dreyfus
    Olivier Tournilhac
    Beatrice Mahe
    Florence Nguyen-Khac
    Claude Lesty
    Frederic Davi
    Hélène Merle-Béral
    Annals of Hematology, 2009, 88 : 1215 - 1221
12345